Impact of Hormone Receptor Status on the Behaviour of
HER2+Breast Cancer

J 2020

Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer

KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL et. al.

Základní údaje

Originální název

Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer

Autoři

KOLAROVA, Iveta (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Ales RYSKA (203 Česká republika), Karel ODRAZKA, Martin DOLEZEL (203 Česká republika), Jaroslav VANASEK (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Jiri PETERA (203 Česká republika), Tomas BUCHLER (203 Česká republika), Milan VOSMIK (203 Česká republika), Katarina PETRAKOVA (203 Česká republika), Petra TERAROVA (203 Česká republika), Zdena VILASOVA (203 Česká republika) a Jiří JARKOVSKÝ (203 Česká republika, garant, domácí)

Vydání

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2020, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.155

Kód RIV

RIV/00216224:14110/20:00117213

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/invivo.12183

UT WoS

000587929100043

Klíčová slova anglicky

Breast cancer; triple positive; HER2-positive; hormone receptors; overall survival; trastuzumab

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 12. 2020 13:08, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Citovat

KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL, Jaroslav VANASEK, Bohuslav MELICHAR, Jiri PETERA, Tomas BUCHLER, Milan VOSMIK, Katarina PETRAKOVA, Petra TERAROVA, Zdena VILASOVA a Jiří JARKOVSKÝ. Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2020, roč. 34, č. 6, s. 3441-3449. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12183.

@article{1703238,
   author = {Kolarova, Iveta and Dušek, Ladislav and Ryska, Ales and Odrazka, Karel and Dolezel, Martin and Vanasek, Jaroslav and Melichar, Bohuslav and Petera, Jiri and Buchler, Tomas and Vosmik, Milan and Petrakova, Katarina and Terarova, Petra and Vilasova, Zdena and Jarkovský, Jiří},
   article_location = {ATHENS},
   article_number = {6},
   doi = {http://dx.doi.org/10.21873/invivo.12183},
   keywords = {Breast cancer; triple positive; HER2-positive; hormone receptors; overall survival; trastuzumab},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer},
   url = {http://iv.iiarjournals.org/content/34/6/3441.full.pdf},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1703238
AU  - Kolarova, Iveta - Dušek, Ladislav - Ryska, Ales - Odrazka, Karel - Dolezel, Martin - Vanasek, Jaroslav - Melichar, Bohuslav - Petera, Jiri - Buchler, Tomas - Vosmik, Milan - Petrakova, Katarina - Terarova, Petra - Vilasova, Zdena - Jarkovský, Jiří
PY  - 2020
TI  - Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer
JF  - In vivo
VL  - 34
IS  - 6
SP  - 3441-3449
EP  - 3441-3449
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Breast cancer
KW  - triple positive
KW  - HER2-positive
KW  - hormone receptors
KW  - overall survival
KW  - trastuzumab
UR  - http://iv.iiarjournals.org/content/34/6/3441.full.pdf
L2  - http://iv.iiarjournals.org/content/34/6/3441.full.pdf
N2  - Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.
ER  -

KOLAROVA, Iveta, Ladislav DUŠEK, Ales RYSKA, Karel ODRAZKA, Martin DOLEZEL, Jaroslav VANASEK, Bohuslav MELICHAR, Jiri PETERA, Tomas BUCHLER, Milan VOSMIK, Katarina PETRAKOVA, Petra TERAROVA, Zdena VILASOVA a Jiří JARKOVSKÝ. Impact of Hormone Receptor Status on the Behaviour of HER2+Breast Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2020, roč.~34, č.~6, s.~3441-3449. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12183.

Podrobný výpis o publikaci